John Henderson Biography and Net Worth

Director of Cytokinetics

John T. Henderson, M.D., Ch.B. has served as a member of our Board of Directors since February 2009. Since December 2000, Dr. Henderson has served as a consultant to the pharmaceutical industry as president of Futurepharm LLC. Dr. Henderson consulted for NeuroVia Inc. as Chief Development Officer and was an Executive Officer of this privately held company until October 2018. Until his retirement in December 2000, Dr. Henderson was with Pfizer Inc. for more than 25 years, most recently as a Vice President in the Pfizer Pharmaceuticals Group. Dr. Henderson previously held Vice Presidential–level positions with Pfizer in Research and Development in Europe and later in Japan. He was also Vice President, Medical for Pfizer’s Europe, U.S., and International Pharmaceuticals groups. Dr. Henderson has served on the Board of Directors of Myriad Genetics, Inc., a healthcare diagnostics company, since 2004, and has served as Chairman of Myriad’s Board of Directors since April 2005. He served on the Board of Directors of Myrexis, Inc. (formerly Myriad Pharmaceuticals, Inc.) from June 2009 until January 2013. He also serves as Chairman of the Board of Directors of a privately held pharmaceutical research and development company. Dr. Henderson earned his B.S. and medical degrees from the University of Edinburgh and is a Fellow of the Royal College of Physicians (Ed.) and the Faculty of Pharmaceutical Medicine.

What is John T. Henderson's net worth?: The estimated net worth of John T. Henderson is at least $1.88 million as of December 11th, 2024. Mr. Henderson owns 38,461 shares of Cytokinetics stock worth more than $1,879,589 as of December 21st. This net worth evaluation does not reflect any other investments that Mr. Henderson may own. Learn More about John T. Henderson's net worth.
How do I contact John T. Henderson?: The corporate mailing address for Mr. Henderson and other Cytokinetics executives is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. Cytokinetics can also be reached via phone at (650) 624-3000 and via email at [email protected]. Learn More on John T. Henderson's contact information.
Has John T. Henderson been buying or selling shares of Cytokinetics?: John T. Henderson has not been actively trading shares of Cytokinetics over the course of the past ninety days. Learn More on John T. Henderson's trading history.
Who are Cytokinetics' active insiders?: Cytokinetics' insider roster includes Muna Bhanji (Director), Robert Blum (President and Chief Executive Officer), Santo Costa (Director), David Cragg (Insider), L. Gage (Director), Robert Harrington (Director), John Henderson (Director), Ching Jaw (CFO), Edward Kaye (Director), Fady Malik (EVP), B. Parshall (Director), Mark Schlossberg (SVP), Sandford Smith (Director), Wendall Wierenga (Director), and Robert Wong (CAO). Learn More on Cytokinetics' active insiders.
Are insiders buying or selling shares of Cytokinetics?: During the last year, insiders at the biopharmaceutical company sold shares 48 times. They sold a total of 454,133 shares worth more than $28,606,030.33. The most recent insider tranaction occured on December, 16th when Director Wendall Wierenga sold 742 shares worth more than $36,068.62. Insiders at Cytokinetics own 3.4% of the company. Learn More about insider trades at Cytokinetics.
Information on this page was last updated on 12/16/2024.

John T. Henderson Insider Trading History at Cytokinetics

John T. Henderson Buying and Selling Activity at Cytokinetics

Cytokinetics Company Overview

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Today's Range

Now: $48.87

$46.85

$50.32

50 Day Range

MA: $52.09

$46.36

$58.62

2 Week Range

Now: $48.87

$36.24

$110.25

Volume

3,805,196 shs

Average Volume

1,988,956 shs

Market Capitalization

$5.77 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.8

Most People Are Dead Wrong.

From Brownstone Research | Ad

I call it my AI Retirement Playbook. I recommend you check it out now.